Brazil Oncology Drugs Market Analysis Report 2022 to 2030

Brazil Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Brazil oncology drugs market will reach a value of $12.7 Bn from $4.9 Bn in 2022, growing at a CAGR of 12.6% during 2022-2030. The oncology drug market in Brazil is dominated by a few large pharmaceutical companies such as EMS Pharma, Eurofarma, and Takeda Pharma. The oncology market in Brazil is segmented by different therapeutic areas and by different treatment types. The major factors affecting the Brazilian oncology drugs market are the high cost of the drugs, and the structured reimbursement system for the treatment.

ID: IN10BRPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Dr. Vishwa Modhia

Buy Now

Brazil Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Brazil oncology drugs market will reach a value of $12.7 Bn from $4.9 Bn in 2022, growing at a CAGR of 12.6% during 2022-30. In 2022, Brazil spent 8.2% of its Gross Domestic Product (GDP) on health, of which 4.4% come from private spending and 3.8% from public spending. The number of incident cases of oncological conditions in Brazil was 592,212 in 2020. Among them, the highest cases were of prostate and breast cancer.

In Brazil, the sale of oncology drugs increased by 30% on average between February 2021 and January 2022 when compared to the previous 12 months. Brazil has made significant progress toward universal healthcare and is one of the world's top pharmaceutical markets, but it is still recovering from its worst recession ever and the effects of its disastrous COVID-19 response.

brazil oncology drugs market

Market Dynamics

Market Growth Drivers Analysis

In comparison to the previous 12 months, the sale of oncology drugs increased by an average of 30% between February 2021 and January 2022, which gives an idea about the good progress of the oncology drugs market in Brazil. The increase in the number of oncology patients has also acted as a growth driver.

Market Restraints

Drugs for human use are subject to one of the highest tax burdens in Brazil, amounting to an average of 31.3% of the consumer price, which prevents the products from being sold to consumers at even lower prices. Around 57% of health spending is on private insurance, with out-of-pocket expenses, primarily for medications, accounting for more than half of that amount.

Competitive Landscape

Key Players

EMS Pharma (BRA)
Eurofarma (BRA)
Sanofi (BRA)
Takeda Pharma (BRA)
Hoffmann-La Roche Ltd
Novartis AG
Gilead Sciences Inc
Bayer AG

Notable Recent Deals

July 2022: The next-gen sequencing-based precision oncology diagnostic lab will enable Hospital de Base in São José do Rio Preto, Brazil, to provide in-house clinical testing to patients in the area and to advance clinical research. Under the terms of the agreement, Geneseeq, which has headquarters in Toronto and Nanjing, will jointly build a new lab with the Brazilian hospital and help it establish a variety of the firm’s genomic profiling tests, including its comprehensive pan-cancer gene panels and several cancer type-specific gene panels.

Regulations and Reimbursement

Brazilian law has established deadlines for the approval of registrations and post-registrations in Brazil, granting predictability to pharmaceutical companies located in the country. In 2019, the CMED Resolution of the Drug Market Regulation Chamber (CMED, in Portuguese) was published establishing procedures for the release of the Factory Price for Over-The-Counter (OTC) drugs.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.